IPSE'S AUTHORS LAST 24h
Check all the Authors in the last 24h
IPSEs IN THE LAST 24H
  • Chandrachur Singh
    Chandrachur Singh “The opposition - a consortium of nearly two dozen parties - has not been able to rally people around economic distress despite raising it as a prominent election issue. The problem with the opposition is that it is a coming together of parties with divergent views whose only agenda seems to be to dislodge Modi. To the people, that doesn't seem to be a good enough agenda. The fact that the opposition has not projected a face against Modi is also an issue. Rahul Gandhi is slowly emerging as that leader, but in terms of perception, he is still far behind Modi.” 5 hours ago
  • Neelanjan Sircar
    Neelanjan Sircar “A large part of what the BJP [Bharatiya Janata Party] does is thinking about how to centralise all political attribution on Modi. Its campaign promises are pitched as Modi's guarantees. This is the strategy of a party where the leader is a cult figure and the party is the vehicle for the leader. Whether it's economic distress or even issues like violence in Manipur, Modi is not directly sullied. People may blame other leaders of the BJP. In regional elections, as a consequence, BJP might be voted out. But it is not anger against Modi.” 5 hours ago
  • Benjamin Netanyahu
    Benjamin Netanyahu “The idea that we will stop the war before achieving all its objectives is out of the question. We will enter Rafah and we will eliminate the Hamas battalions there - with or without a deal, in order to achieve the total victory.” 5 hours ago
  • Nour Odeh
    Nour Odeh “For a while, there was a lot of cautious optimism up until this morning, and then the prime minister announced he will order an invasion of Rafah with or without a deal - in essence trampling all of these ceasefire talks. This is what the families of the captives had feared. This is what the negotiators feared. Netanyahu's comments came after he held meetings with the most right-wing members of his coalition government, including Itamar Ben-Gvir. It's interesting, every time Blinken comes to the region - catching the tailwind of some optimism - something like this happens, and he ends up going home with nothing to show for all this political momentum.” 5 hours ago
  • Randall Kuhn
    Randall Kuhn “Put simply, the situation in Gaza is it's completely intolerable at this point. We're on the border of famine and for us as a university, we have to reckon with the fact that every university in Gaza has been destroyed. As a professor, I find it repugnant to sit by while Palestinian professors are being killed, while academic buildings are being bombed relentlessly.” 5 hours ago
View All IPSEs inserted in the Last 24h
NEW CONTEXTS IN THE LAST 24H
  • No New Contexts inserted in the last 24 hours
View All New Contexts inserted in the last 24h

#Pfizer

Page with all the IPSEs stored in the archive with the tag #Pfizer linked to them.
The IPSEs are presented in chronological order based on when the IPSEs have been pronounced.

“The United States is buying another half a billion doses of Pfizer to donate to low- and middle-income countries around the world. We're not going to solve this crisis with half measures or middle-of-the-road ambitions. We need to go big. And we need to do our part - governments, the private sector, civil society leaders, philanthropists.”

author
President of the United States
Read More

“Included in our plans are also the questions of how reliable the partners, how much a partner has proven that he can deliver, and this is exactly what BioNTech/Pfizer has done. We went through initial difficulties, and the experience of overcoming together difficulties, working hard together and sticking together ... was a very good experience that builds trust. On this trust, I think we can also build the future.”

author
President of the European Commission
Read More

“This is very encouraging news. It means more people vaccinated, and sooner. Because for AstraZeneca, just like we were for Pfizer and Moderna, we are ready to get doses rolling. Vaccines will keep arriving faster and faster as we head into the spring.”

author
Prime Minister of Canada
Read More

“These results [4 weeks after the first dose Pfizer reduced risk of hospitalisation by up to 85% and Oxford-AstraZeneca by up to 94%] are very encouraging and have given us great reasons to be optimistic for the future. We now have national evidence – across an entire country – that vaccination provides protection against COVID-19 hospitalisations. Roll out of the first vaccine dose now needs to be accelerated globally to help overcome this terrible disease.”

author
Professor at the University of Edinburgh
Read More

“The next few weeks will be challenging when it comes to deliveries. That said, Dr. Bourla assured me that hundreds of thousands of Pfizer doses will be delivered the week of February 15 and in the weeks to follow.”

author
Prime Minister of Canada
Read More

“We have good news. We will receive 8,000 Pfizer vaccines from Serbia. Today, President Vucic confirmed to me that Serbia will help us with vaccines from their supply, which we will pay at the purchase price. This is an act of solidarity by our neighbour and strengthens our friendship. Negotiations are underway on the technical procedures for the vaccination, and health professionals, people with chronic diseases, adults and other at risk groups will be vaccinated with the first batch.”

author
Prime Minister of North Macedonia
Read More

“Americans want us to do a scientific review, but I think they also want us to make sure we’re not wasting time on paperwork as opposed to going forward with the decision.”

author
U.S. Food and Drug Administration Commissioner
Read More

“We’re working very closely with our UK partners to understand what went on with respect to those allergic reactions. FDA is the gold standard for regulatory approval or authorization of medical products. If our career scientists say that the vaccine is safe and effective, I have complete confidence in that decision, and I think the American people should as well.”

author
U.S. Food and Drug Administration Commissioner
Read More

“Canadians can have confidence ... the vaccine was authorized only after a thorough assessment of the evidence demonstrated it had met Health Canada's strict standards for efficacy, safety and quality. It's an exceptional day for Canada. In a year when we haven't had a lot of good news, this is a bit of good news and we should acknowledge that. We are always on the lookout for more serious adverse events. It is still a vaccine and there are potential risks even if they are rare. That's why it's important that we still continue to monitor it. Because these vaccines will be used in otherwise healthy people ... our tolerance for safety issues is very, very low.”

author
Chief medical adviser to Health Canada's deputy minister
Read More

“This is historic. We couldn't be more proud that Pfizer and BioNTech were able to bring to Canada the first COVID-19 vaccine. We think this represents a monumental change in the way that we are fighting the pandemic, and hopefully represents the first big step towards normalcy. I would reassure Canadians that the scientific rigour and regulatory oversight that went into this product is as robust, if not more robust, than any other vaccine that's been brought to market.”

author
President of Pfizer Canada
Read More

“If I use the U.K. as an example, we got approval at 1:00 am in the morning. We approved [the] release of the vaccine and shipped it within 24 hours. Certainly from the discussions that we've had, Canada is in a good position to approve the vaccine shortly. Upon approval, we then release the vaccine and then it is shipped. We've already produced the vaccine and reserved doses for Canada.”

author
Chief business and chief commercial officer of Germany's BioNTech
Read More

“Today is a great day for science and humanity. The first set of results from our phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19. We are reaching this critical milestone in our vaccine development programme at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”

author
Pfizer chairman and chief executive
Read More
IPSEs by Author
IPSEs by Country
arrow